Peptide Initiative

Peptides · Peptide comparison

Apelin-13 vs Thymosin Beta-4

A natural heart hormone that helps your cardiovascular system work better and supports healthy blood flow throughout your body.

The body's natural healing peptide that accelerates tissue repair and reduces inflammation

  • Healing & Recovery
  • Healing & Recovery

At a glance

Quick comparison

Dose rangeApelin-13100–100 nmol/minThymosin Beta-42–5 mg
FrequencyApelin-13Once dailyThymosin Beta-4Twice weekly
AdministrationApelin-13Intravenous (IV)Thymosin Beta-4Subcutaneous injection
Cycle lengthApelin-13Ongoing/indefiniteThymosin Beta-48-12 weeks
Onset speedApelin-13Moderate (1-2 weeks)Thymosin Beta-4Moderate (1-2 weeks)
Evidence levelApelin-13Moderate human trials (Phase 1-2)Thymosin Beta-4Moderate human trials (Phase 1-2)

Efficacy

Benefit ratings

Cardiovascular Support

Apelin-1382%
Thymosin Beta-4No recorded rating

Heart Function & Strength

Apelin-1378%
Thymosin Beta-4No recorded rating

Blood Flow & Circulation

Apelin-1374%
Thymosin Beta-4No recorded rating

Wound Healing

Apelin-13No recorded rating
Thymosin Beta-495%

Inflammation Reduction

Apelin-13No recorded rating
Thymosin Beta-488%

Tissue Regeneration

Apelin-13No recorded rating
Thymosin Beta-492%

Technical data

Compound specifications

Apelin-13

Molecular formula
C69H111N23O16S
Molecular weight
1550.8 Da
Half-life
Minutes in plasma; varies by route of administration
Bioavailability
~90-95% (subcutaneous injection)
CAS number
Not yet assigned (research compound)

Thymosin Beta-4

Molecular formula
C212H350N56O78S
Molecular weight
4963
Half-life
Dose-dependent (increases with higher doses)
Bioavailability
100% (subcutaneous and intravenous)
CAS number
77591-33-4

Protocols

Dosing compared

Apelin-13

Intravenous

  • 30 nmol/minContinuous infusion · 5 minutes per dose step (research setting)Apelin-13 is a research peptide given as a short drip into a vein in studies, not by self-injection. This low rate was the first step tested in a human heart study. [4]
  • 100 nmol/minContinuous infusion · 5 minutes per dose step (research setting)Middle infusion rate used in the human heart study. It increased the heart's output and relaxed blood vessels. [4]
  • 300 nmol/minContinuous infusion · 5 minutes per dose step (research setting)Highest infusion rate tested in the same human study, producing the strongest effect on heart output and blood pressure. [4]

Thymosin Beta-4

Subcutaneous injection

  • 2-5 mg (community injectable practice for 'TB-500')Once or twice weekly · 4-6 week loading phase, then weekly maintenanceDocumented community/research-practice injectable dosing for tissue repair; thymosin beta-4 has ~100% bioavailability by the subcutaneous route [1]. Not an FDA-approved use.

Topical ophthalmic (eye drops)

  • 0.1% (1 mg/mL) RGN-259 solution, 1 dropSeveral times daily (e.g. up to 5x/day) · 4 weeks0.1% RGN-259 ophthalmic solution used in phase III neurotrophic keratopathy and dry-eye trials, applied as eye drops several times daily for ~4 weeks [5].

Intravenous injection

  • 450-1200 mgIV push daily for the first 3 days, then weekly · Total of 7 doses over ~5 weeksDoses studied in the RGN-352 acute myocardial infarction clinical program, given IV after PCI [6].

Applications

Best suited for

Apelin-13

Research into cardiovascular health and heart function
Apelin-13 is particularly well-suited for individuals focused on research into cardiovascular health and heart function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [4][7].
Understanding how the body naturally protects the heart
Apelin-13 is particularly well-suited for individuals focused on understanding how the body naturally protects the heart. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [3].
Exploring potential treatments for heart failure
Apelin-13 is particularly well-suited for individuals focused on exploring potential treatments for heart failure. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [4][7].
Studying mechanisms of heart muscle strength
Apelin-13 is particularly well-suited for individuals focused on studying mechanisms of heart muscle strength. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [4].

Thymosin Beta-4

Post-Surgery Recovery
Accelerates healing of surgical wounds and reduces post-operative inflammation and scarring
Chronic Wound Management
Helps pressure ulcers, venous stasis ulcers, and other slow-healing wounds progress faster
Tissue Regeneration
Supports repair of damaged tissues from injury, burns, or degenerative conditions

Safety profile

Side effects

Apelin-13

Common

  • Mild changes in blood pressure
  • Minimal systemic effects in animal studies
  • Headache (theoretical, based on blood pressure effects)
  • Flushing or warmth at injection site
  • Mild inflammation at injection site
  • Dizziness if blood pressure drops too quickly
  • Allergic reactions to the peptide
  • Heart rhythm changes (requires monitoring)
  • Blood pressure, heart rate, cardiac function

Serious

  • Severe allergic reaction

Thymosin Beta-4

Common

  • Injection site redness
  • Injection site swelling

Uncommon

  • Temporary mild headache
  • Mild bruising at injection site
  • Transient fatigue

Serious

  • Allergic reaction

Research status

Safety & evidence

Apelin-13

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Apelin-13 is a research compound with no human clinical trials or FDA approval. All safety data comes from animal studies and in vitro mechanistic work showing beneficial effects on vascular function and cardiac remodeling. However, animal models do not predict human safety, and the peptide's effects on immune regulation in humans remain untested. No dose-ranging studies, pharmacokinetics, or organ accumulation data exist in humans. The APJ receptor is expressed in multiple tissues including brain, raising concerns about off-target neurological effects at high doses.

Contraindications

  • Currently under investigation - not for human clinical use
  • May interact with blood pressure medications (in theory)
  • Should not be used if allergic to peptides or component amino acids
  • Pregnant or breastfeeding individuals should avoid

Thymosin Beta-4

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Thymosin Beta-4 is a naturally occurring peptide found in all cells and body fluids in the human body. Clinical trials have demonstrated excellent safety even at very high doses. IV studies showed doses up to 1260 mg were well tolerated with no serious adverse events.

Contraindications

  • Active systemic infections
  • Severe immunosuppression
  • Hypersensitivity to thymosin or any component
  • Pregnancy (insufficient safety data)

Decision guide

Which is right for you?

Apelin-13

Choose Apelin-13 if…

  • Research into cardiovascular health and heart function
  • Understanding how the body naturally protects the heart
  • Exploring potential treatments for heart failure
  • Studying mechanisms of heart muscle strength

Thymosin Beta-4

Choose Thymosin Beta-4 if…

  • Recovering from injuries or surgery
  • Improving wound healing speed
  • Reducing inflammation
  • Minimizing scar formation